Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

Article  PubMed  Google Scholar 

Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112–20.

Article  PubMed  PubMed Central  Google Scholar 

Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leiva O, AbdelHameid D, Connors JM, Cannon CP, Bhatt DL. Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(5):619–34.

Article  PubMed  PubMed Central  Google Scholar 

Chao A, Thun MJ, Connell CJ, McCullough ML, Jacobs EJ, Flanders WD, et al. Meat consumption and risk of colorectal cancer. JAMA. 2005;293(2):172–82.

Article  CAS  PubMed  Google Scholar 

Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106(11):1911–21; quiz 22.

Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102(17):1344–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vogel JD, Felder SI, Bhama AR, Hawkins AT, Langenfeld SJ, Shaffer VO, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2022;65(2):148–77.

Article  PubMed  Google Scholar 

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329–59.

Article  PubMed  Google Scholar 

Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32.

Article  CAS  PubMed  Google Scholar 

Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17(1):38–44.

Article  PubMed  Google Scholar 

Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393–422.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

Article  PubMed  Google Scholar 

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(9):1109–33.

Article  PubMed  PubMed Central  Google Scholar 

von Mehren M, Kane JM, Riedel RF, Sicklick JK, Pollack SM, Agulnik M, et al. NCCN Guidelines(R) Insights: Gastrointestinal Stromal Tumors, Version 2.2022. J Natl Compr Canc Netw. 2022;20(11):1204–14.

Article  Google Scholar 

Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. Ann Surg. 2017;265(1):185–91.

Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502.

Article  PubMed  PubMed Central  Google Scholar 

Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439–57.

Article  CAS  PubMed  Google Scholar 

Patrzalek P, Wysokinski WE, Kurmann RD, Houghton D, Hodge D, Kuczmik W, et al. Cancer-associated non-bacterial thrombotic endocarditis-Clinical series from a single institution. Am J Hematol. 2024;99(4):596–605.

Article  CAS  PubMed  Google Scholar 

Kurmann RD, Klarich KW, Wysokinska E, Houghton D, Kaminska A, Patrzalek P, Hodge D, Wysokinski WE. Echocardiographic findings in cancer-associated non-bacterial thrombotic endocarditis. Clinical series of 111 patients from single institution. Eur Heart J Cardiovasc Imaging. 2024;jeae112. https://doi.org/10.1093/ehjci/jeae112.

Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13(3):484–5.

Article  PubMed  Google Scholar 

Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to5-fluorouracil. Ann Oncol. 2002;13(5):797–801.

Article  CAS  PubMed  Google Scholar 

Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191–202.

Article  CAS  PubMed  Google Scholar 

Zafar A, Drobni ZD, Mosarla R, Alvi RM, Lei M, Lou UY, et al. The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm. JACC CardioOncol. 2021;3(1):101–9.

Article  PubMed  PubMed Central  Google Scholar 

Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82.

Article  CAS  PubMed  Google Scholar 

Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17(4):729–36.

Article  CAS  PubMed  Google Scholar 

Wang Y, Wang W, Dong H, Wang G, Chen W, Chen J, et al. Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: A retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity. Front Oncol. 2023;13:1017237.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487–93.

Article  CAS  PubMed  Google Scholar 

Chong JH, Ghosh AK. Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions. Interv Cardiol. 2019;14(2):89–94.

Article  PubMed  PubMed Central  Google Scholar 

Rajaeinejad M, Parhizkar-Roudsari P, Khoshfetrat M, Kazemi-Galougahi MH, Mosaed R, Arjmand R, et al. Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment. Cardiovasc Toxicol. 2024;24(2):184–98.

Article  CAS  PubMed  Google Scholar 

Zafar A, Drobni ZD, Lei M, Gongora CA, Quinaglia T, Lou UY, et al. The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. PLoS ONE. 2022;17(4):e0265767.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leiva O, Bohart I, Ahuja T, Park D. Off-Target Effects of Cancer Therapy on Development of Therapy-Induced Arrhythmia: A Review. Cardiology. 2023;148(4):324–34.

Article  CAS  PubMed  Google Scholar 

Beitzen-Heineke A, Rolling CC, Seidel C, Erley J, Molwitz I, Muellerleile K, Saering D, Senftinger J, Börschel N, Engel NW, Bokemeyer C, Adam G, Tahir E, Chen H. Long-term cardiotoxicity in germ cell cancer survivors after platinum-based chemotherapy: cardiac MR shows impaired systolic function and tissue alterations. Eur Radiol. 2024;34(6):4102–12. https://doi.org/10.1007/s00330-023-10420-w.

Feng G, Zhou X, Chen J, Li D, Chen L. Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data. Front Oncol. 2023;12:1012093. https://doi.org/10.3389/fonc.2022.1012093.

Ashraf N, Kim R. Treatment of Gastric and Gastroesophageal Cancers—Do We Really Need Anthracyclines? JAMA Oncol. 2017;3(9):1172–3.